Researchers found that a cognitive-behavioral sleep therapy intervention helps adolescent night owls combat depression by aligning their natural sleep rhythms with daily responsibilities.
Category: Cognitive Behavioral Therapy
Jennifer L. Martin, PhD, speaks about the challenges faced by people with insomnia disorder in accessing CBT-I and pharmaceuticals, as well as posits solutions.Read More
A paper details a health economic analysis of Somryst, including changes in healthcare resource use, associated costs, and insomnia severity.Read More
ResMed Acquires Mementor. Its Insomnia Solution Builds ResMed’s Digital Sleep Medicine Portfolio in Germany.
ResMed has acquired Leipzig, Germany-based health tech company mementor; the deal was completed on August 1.Read More
Insomnia is linked with anxiety and depression, and a clinical trial evaluates the impact of Somryst on these comorbidities.Read More
Hundreds of thousands of insomnia patients will be offered digital cognitive behavioral therapy via the app Sleepio instead of sleeping pills.Read More
Two abstracts presented at World Sleep 2022 provide data on Somryst’s efficacy at six months and on its use in older adults.Read More
By targeting insomnia and effectively treating it with CBT-I, depression can be effectively prevented by over 50% in community dwelling older adults with insomnia.Read More
SleepCogni, Developers of Insomnia Device with Cognitive Behavioral Therapy Platform, Raises $2M to Enter US Market
The investment will help prepare the device for volume manufacturing, develop the clinician and patient-led online platform, and achieve first sales.Read More
OptumRx will offer and administer standard pharmacy benefit coverage for members who choose to add the product to their formularies.Read More
This clinical review provides GPs with a description of a four-session insomnia treatment program that is tailored to the time limitations, knowledge, and capacity of general practice staff.Read More
Serve You Rx will provide prescription benefit coverage of Somryst to their members as a standard offering on all formularies.Read More
Net proceeds from the business combination will be used to further capitalize Pear’s position by investing in commercialization of Pear’s three FDA-authorized products, advancing Pear’s pipeline, and scaling its end-to-end platform.Read More